Background: Since December 2019, there have been cases of infectious pneumonia of unknown cause in Wuhan, Hubei Province, China. On January 12, 2020, the World Health Organization (WHO) named it COVID-19. There are few studies on the clinical characteristics of patients with COVID-19, and results vary widely in sample sizes.
Methods: Chinese and English databases were searched with "Infectious pneumonia", "COVID-19", "CT", "SARS-COV-2", and "Diagnose" as keywords. Rev Man 5.3 software provided by the Cochrane system was used to assess the quality of the included literature.
Results: Of the 18 included studies, ground-glass shadow was the most common computed tomography (CT) sign [95% confidence interval (CI): 0.79-0.97], followed by thickening of the blood vessels (95% CI: 0.63-0.78), and pleural thickening (95% CI: 0.02-0.15). Of the 18 studies, 12 reported that the lesions were externally subpleural (95% CI: 0.132-0.173), and 6 reported that the lesions were distributed in a single lobe (95% CI: 0.598-0.841). The heterogeneity test results showed that the morphology of the lesions was cord-like (95% CI: 0.092-0.172), grid-like (95% CI: 0.152-0.193), patchy (95% CI: 0.192-0.313), and nodular (95% CI: 0.591-0.745).
Discussion: Ground-glass opacity was a typical CT manifestation for patients with infectious pneumonia, and CT signs were instrumental in diagnosing this disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21037/apm-21-2101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of a Multiplex PCR Assay for Rapid Diagnosis and Antibiotic Utilization in Trauma Intensive Care Unit Patients with Ventilator-Acquired Pneumonia.
Surg Infect (Larchmt)
March 2025
Division of Trauma and Acute Care Surgery, Department of Surgery, Atrium Health Wake Forest Baptist Hospital, Winston-Salem, North Carolina, USA.
Ventilator-associated pneumonia (VAP) is a frequent complication in injured patients. Multiplex polymerase chain reaction (PCR) facilitates rapid identification of many respiratory pathogens prior to formal culture results. Our objective was to evaluate the effect of multiplex PCR implementation in a trauma intensive care unit (TICU) on antibiotic utilization and de-escalation.
View Article and Find Full Text PDFAnimal models of post-acute COVID-19 syndrome: a call for longitudinal animal studies.
Front Immunol
March 2025
Department of Public Laboratory, The Third People's Hospital of Kunming City/Infectious Disease Clinical Medical Center of Yunnan Province, Kunming, Yunnan, China.
Animal models are indispensable for unraveling the mechanisms underlying post-acute sequelae of COVID-19 (PASC). This review evaluates recent research on PASC-related perturbations in animal models, drawing comparisons with clinical findings. Despite the limited number of studies on post-COVID conditions, particularly those extending beyond three months, these studies provide valuable insights.
View Article and Find Full Text PDFAssociation between SARS-CoV-2 infection and anti-apolipoprotein A-1 antibody in children.
Front Immunol
March 2025
Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, Geneva, Switzerland.
Background And Aims: Autoantibodies against apolipoprotein A-1 (AAA1) are elicited by SARS-CoV-2 infection and predict COVID-19 symptoms persistence at one year in adults, but whether this applies to children is unknown. We studied the association of SARS-CoV-2 exposure with AAA1 prevalence in children and the association of AAA1 seropositivity with symptom persistence.
Methods: Anti-SARS-CoV-2 and AAA1 serologies were examined in 1031 participants aged 6 months to 17 years old from the prospective SEROCOV-KIDS cohort and recruited between 12.
Prevalence of bacteria, fungi, and virus coinfections with SARS-CoV-2 Omicron variant among patients with severe COVID-19 in Guangzhou, China, winter 2022.
Biosaf Health
April 2024
Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510440, China.
The status of coinfection during the national outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5.2 or BF.
View Article and Find Full Text PDFEfficacy and Safety of Intravenous-to-Oral Lascufloxacin Switch Therapy in Community-Onset Pneumonia: A Single-Arm, Open-Label Clinical Trial.
Cureus
March 2025
Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, JPN.
Background And Objective: For treating community-acquired pneumonia (CAP) in adults, early switching from injectable to oral antimicrobials (switch therapy) is accepted once the clinical course is favorable. Lascufloxacin (LSFX) is a quinolone antibacterial agent, available in intravenous and oral formulations, demonstrating antibacterial activity against a relatively broad spectrum of community-onset pneumonia (COP). No switch therapy using the same drug from injectable to oral antimicrobials has been reported; therefore, we conducted the study to confirm the efficacy and safety of the switch therapy using LSFX.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!